| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | INSP | Common Stock | Tax liability | -$57.2K | -314 | -10.19% | $182.15 | 2.77K | Feb 9, 2025 | Direct | F1, F2 |
| transaction | INSP | Common Stock | Award | $0 | +5.08K | +183.45% | $0.00 | 7.84K | Feb 13, 2025 | Direct | F3 |
| transaction | INSP | Common Stock | Options Exercise | $1.69M | +25K | +318.76% | $67.63 | 32.8K | Feb 13, 2025 | Direct | |
| transaction | INSP | Common Stock | Sale | -$446K | -2.5K | -7.61% | $178.54 | 30.3K | Feb 13, 2025 | Direct | F4, F5 |
| transaction | INSP | Common Stock | Sale | -$179K | -1K | -3.3% | $179.41 | 29.3K | Feb 13, 2025 | Direct | F4, F6 |
| transaction | INSP | Common Stock | Sale | -$240K | -1.33K | -4.53% | $180.79 | 28K | Feb 13, 2025 | Direct | F4, F7 |
| transaction | INSP | Common Stock | Sale | -$686K | -3.77K | -13.46% | $181.90 | 24.2K | Feb 13, 2025 | Direct | F4, F8 |
| transaction | INSP | Common Stock | Sale | -$593K | -3.24K | -13.37% | $182.90 | 21K | Feb 13, 2025 | Direct | F4, F9 |
| transaction | INSP | Common Stock | Sale | -$467K | -2.54K | -12.1% | $183.79 | 18.5K | Feb 13, 2025 | Direct | F4, F10 |
| transaction | INSP | Common Stock | Sale | -$638K | -3.45K | -18.7% | $184.81 | 15K | Feb 13, 2025 | Direct | F4, F11 |
| transaction | INSP | Common Stock | Sale | -$711K | -3.82K | -25.48% | $185.84 | 11.2K | Feb 13, 2025 | Direct | F4, F12 |
| transaction | INSP | Common Stock | Sale | -$625K | -3.34K | -29.87% | $186.96 | 7.84K | Feb 13, 2025 | Direct | F4, F13 |
| transaction | INSP | Common Stock | Sale | -$110K | -584 | -7.45% | $187.66 | 7.26K | Feb 13, 2025 | Direct | F4 |
| holding | INSP | Common Stock | 167 | Feb 9, 2025 | Held by son | ||||||
| holding | INSP | Common Stock | 166 | Feb 9, 2025 | Held by daughter |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | INSP | Stock Option (Right to Buy) | Options Exercise | $0 | -25K | -100% | $0.00 | 0 | Feb 13, 2025 | Common Stock | 25K | $67.63 | Direct | F14 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | Reflects shares of common stock that were withheld by the Issuer to satisfy taxes incident to vesting of a restricted stock unit award. |
| F2 | Includes 25 shares acquired under the Inspire Medical Systems, Inc. 2018 Employee Stock Purchase Plan on December 31, 2024. |
| F3 | Represents an award of restricted stock units, which vests in three equal annual installments commencing on February 13, 2026. Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. |
| F4 | The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 13, 2024 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. |
| F5 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $178.08 to $178.93. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F6 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $179.12 to $179.75. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F7 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $180.29 to $181.27. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F8 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $181.30 to $182.26. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F9 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $182.30 to $183.27. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F10 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $183.31 to $184.30. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F11 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $184.33 to $185.31. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F12 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $185.35 to $186.32. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F13 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $186.35 to $187.29. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F14 | Fully vested and exercisable. |
Executive Vice President, Patient Access and Therapy Development